Absci Corp closed a $100 million underwritten offering, including a $40 million strategic Equity infusion from Eli Lilly, lifting cash on hand to $201.1 million and extending its operating runway into the second half of 2028. The larger cash buffer supports continued R&D on its AI‑designed ABS‑201 therapy and reduces financing risk for investors.

Key Highlights

  • Absci posted interim Phase 1 data for ABS‑201 showing a half‑life of at least 65 days and favorable safety profile.
  • The infusion increased cash, cash equivalents, and marketable securities to $201.1 million, extending the firm's operating runway.
  • The company's market cap lifted to roughly $1.6 billion, reflecting investor optimism as shares have climbed 160.7% year-to-date.
  • The Capital boost provides latitude to advance the pipeline without resorting to dilutive measures, lowering immediate financing pressure.

The infusion raised cash, cash equivalents and marketable securities to $201.1 million, up from $125.7 million three months earlier, and extends the firm’s operating runway well into the second half of 2028. The offering also lifted the company’s market cap to roughly $1.6 billion, reflecting investor optimism as shares have climbed 160.7% year‑to‑date.

$100M Offering Completed

Eli Lilly’s $40 million strategic stake does not convey development rights, but a representative joined Absci (NASDAQ: ABSI)’s Endometriosis Advisory Board, underscoring collaborative intent. This capital boost lowers immediate financing pressure and gives the firm latitude to advance its pipeline without resorting to dilutive measures.

Cash Runway Extended

Cash on hand of $201.1 million now covers projected operating expenses through the latter half of 2028, according to internal forecasts. The second‑quarter loss widened to $33.2 million from $30.6 million a year earlier, driven by a rise in R&D spend to $22.6 million and SG&A to $9.2 million. Revenue slipped to $0.3 million from $0.6 million, reflecting the early‑stage nature of the business.

Nonetheless, the enlarged cash cushion offsets the heightened burn rate, offering investors confidence that the firm can sustain its AI‑driven drug creation platform while seeking out‑partner deals.

Clinical Progress Drives Momentum

Interim pharmacokinetic results indicate a half‑life of at least 65 days, supporting a dosing schedule of two to three injections over six months. Safety signals remained favorable across all single ascending dose cohorts, reinforcing the therapeutic’s tolerability profile. With an estimated 80 million Americans affected by pattern hair loss, the data positions ABS‑201 as a potential new category of treatment.

Upcoming Data Milestones

Absci plans to release interim proof‑of‑concept results for ABS‑201 in the second half of 2026, followed by a full readout in early 2027. The forthcoming data will be key in confirming the antibody’s efficacy and could trigger a valuation re‑rating if outcomes meet expectations. Should the interim results demonstrate strong hair‑regrowth signals, the company may attract additional Partnership capital, potentially compressing its current short‑interest coverage of 11.7 days of average volume.

Investors will watch the upcoming data closely, as it will shape the firm’s near‑term valuation trajectory.